{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:50:23Z","timestamp":1780491023806,"version":"3.54.1"},"reference-count":11,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alberta Innovates Summer Research Studentship Award","award":["P069"],"award-info":[{"award-number":["P069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This study retrospectively reviewed data from men with localized prostate cancer treated with external beam radiotherapy (EBRT). We identified 359 men with localized prostate cancer treated with curative EBRT at the Cross Cancer Institute between 2010\u20132011. The volume of seminal vesicles (SVs) treated as well as dose values were extracted. These volumes were compared to gold standard contours drawn by a trained expert based on consensus European Society for Radiotherapy and Oncology (ESTRO) contouring guidelines. Patient and tumor characteristics were extracted for these patients. Memorial Sloan Kettering prostate cancer nomogram was used to assign a predicted risk of SV involvement for each patient based on baseline tumor characteristics. In patients with a predicted risk of SV involvement greater than 15% (n = 184), 86.5% (SD = 18.6) of the base of the SVs were treated with EBRT, compared to 66.7% (SD = 32.6) for patients with a predicted risk of SV involvement less than 15% (n = 175, p &lt; 0.0001). Similarly, the mean percentage of proximal and total SV volumes treated with EBRT was 75.6% (SD = 24.4) and 68.7% (SD = 26.0) for patients with a predicted risk of SV involvement of greater than 15%, compared to 50.3% (SD = 31.0, p &lt; 0.0001) and 41.0% (SD = 27.8, p &lt; 0.0001) for patients with a risk of less than 15%. The results indicate that all parts of the SVs are more likely to be contoured in men with &gt;15% risk of SV involvement than those with &lt;15% risk. However, radiation oncologists still contour a high percentage of SVs in men with &lt;15% risk of SV involvement, suggesting that there may be over-treatment of SVs that increases the risk of rectal or bladder toxicity.<\/jats:p>","DOI":"10.3390\/curroncol30070483","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T02:05:21Z","timestamp":1689041121000},"page":"6587-6595","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Seminal Vesicle Treatment for Localized Prostate Cancer Treated with External Beam Radiotherapy"],"prefix":"10.3390","volume":"30","author":[{"given":"Tanner","family":"Steed","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Chopra","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-5058","authenticated-orcid":false,"given":"Sunita","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Warkentin","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaid","family":"Usmani","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0360-3016(02)03011-0","article-title":"Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume?","volume":"54","author":"Kestin","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clon.2007.03.005","article-title":"When Should the Seminal Vesicles be Included in the Target Volume in Prostate Radiotherapy?","volume":"19","author":"Bayman","year":"2007","journal-title":"Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13014-014-0288-1","article-title":"Optimal contouring of seminal vesicle for definitive radiotherapy of localized prostate cancer: Comparison between EORTC prostate cancer radiotherapy guideline, RTOG0815 protocol and actual anatomy","volume":"9","author":"Qi","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_6","unstructured":"(2023, June 20). College of Physicians; Surgeons of Alberta; Physicians Directory. Available online: https:\/\/search.cpsa.ca\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_9","first-page":"19","article-title":"External validation of memorial sloan kettering cancer center nomogram and prediction of optimal candidate for lymph node dissection in clinically localized prostate cancer","volume":"73","author":"Milonas","year":"2020","journal-title":"Cent. Eur. J. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.juro.2008.08.037","article-title":"The Prognostic Impact of Seminal Vesicle Involvement Found at Prostatectomy and the Effects of Adjuvant Radiation: Data From Southwest Oncology Group 8794","volume":"180","author":"Swanson","year":"2008","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0360-3016(97)00320-9","article-title":"Equivalent 5-year bned in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV","volume":"39","author":"Kaplan","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/7\/483\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:09:35Z","timestamp":1760126975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/7\/483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":11,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["curroncol30070483"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30070483","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]}}}